Overview A Study in Subjects With Retinal Detachment Status: Completed Trial end date: 2002-06-01 Target enrollment: Participant gender: Summary The purpose of this trial is to access the tolerability of INS37217 Intravitreal Injection when administered intravitreally in subjects with macula-on or macula-off rhegmatogenous retinal detachment (RRD). Phase: Phase 1 Details Lead Sponsor: Merck Sharp & Dohme Corp.